IMPORTANCE Recent data support percutaneous revascularization as an alternative to coronary artery bypass grafting in unprotected left main (ULM) coronary lesions. However, the relevance of these trials to current practice is unclear, as patterns and outcomes of ULM percutaneous coronary intervention (PCI) in contemporary US clinical practice are not well studied.
L eft main coronary artery stenosis has traditionally been considered a surgical disease, with clinical practice guidelines recommending coronary artery bypass grafting (CABG) as the preferred treatment. 1, 2 At the same time, revascularization via percutaneous coronary intervention (PCI) of unprotected left main (ULM) coronary artery stenosis has remained necessary for patients at prohibitive or high risk for surgical intervention, 3 representing a small but clinically important population. 4 Subsequent data implied that with improvements in technology and procedural techniques, the efficacy of PCI for left main coronary artery revascularization may approach that seen with surgery. portend a possible paradigm shift in the management of obstructive left main lesions. Despite these developments, to our knowledge, there has not been an assessment of the contemporary practice of ULM PCI in the United States in nearly a decade. 4, 10 While the results of the EXCEL and NOBLE trials 8, 9 may have significant implications for coronary revascularization, their applicability to current practice is unclear. Accordingly, we studied the patient and procedural characteristics associated with ULM PCI in the National Cardiovascular Data Registry (NCDR) CathPCI Registry as well as the clinical outcomes of patients undergoing ULM PCI compared with patients undergoing PCI to other coronary segments as well as with findings reported in recent clinical trials. Understanding current practice for ULM PCI will aid clinicians as they seek to incorporate data from clinical trials into their practices.
Methods

Cohort
The cohort was derived from the NCDR CathPCI Registry, which collects data on patients undergoing PCI at more than 1600 institutions and accounts for greater than 90% of PCI-capable hospitals in the United States. 11, 12 Registry data elements were prospectively defined (http://cvquality.acc.org/ncdr-home). In the CathPCI Registry, each procedure is linked to both the operator and the institution. Data are entered at each institution using a standardized interface and exported to a central repository, where they undergo regular auditing to ensure optimal data integrity. 13 Institutional review board approval was waived for this analysis, as data were derived from a national quality registry. Informed consent was not obtained, as data were deidentified. We identified all PCI procedures performed at an institution participating in the NCDR CathPCI Registry from April 2009 to July 2016 (CathPCI version 4.0 and later). Procedures were excluded if patients had a history of CABG (providing protection to the left main coronary artery via leftsided bypass grafts) or if they presented for PCI with cardiogenic shock or cardiac arrest, as these procedures and patients would likely not be representative of most PCI in practice. Interventions to chronic total occlusion of the left main coronary artery were excluded for similar reasons. Finally, patients undergoing balloon angioplasty alone (ie, without stenting) were excluded, as these cases could represent interventions to temporize patients for CABG.
Covariates of Interest
Baseline patient demographic, clinical, and procedural characteristics were collected from the CathPCI Registry and compared between patients undergoing ULM PCI and patients undergoing all other PCI. Temporal trends of these characteristics were compared in 2-year increments. Data were chosen based on characteristics and comorbidities associated with PCI outcomes and included age, sex, race/ethnicity, insurance payer, tobacco use, comorbid medical conditions, and characteristics of their presentation for PCI. Procedural risk for mortality was estimated using the CathPCI risk model.
14 Procedural data included access site; use of mechanical circulatory support (MCS), stratified into any kind of MCS, use of intraaortic balloon pump (IABP), or use of non-IABP MCS; timing of MCS initiation; procedural medications, including glycoprotein IIb/IIIa use and anticoagulant choice; and lesion and intervention characteristics, including use of atherectomy, stent type, and bifurcation status. Operator and facility data were also collected from the CathPCI database. Trial data from the EXCEL and NOBLE trials were abstracted directly from the published reports.
8,9
Outcomes
In-hospital outcomes were collected from the CathPCI Registry. The primary outcome was in-hospital major adverse clinical events (MACE), which was a composite of death, myocardial infarction (MI), stroke, or emergent CABG. These outcomes were also assessed individually. Emergent CABG was defined as emergent or salvage or with an indication of PCI failure or PCI complication. Outcomes from the EXCEL and NOBLE trials were as published. 
Temporal Trends in ULM PCI
Unprotected left main PCI use has increased over time, from 3054 procedures between quarter 3 of 2009 and quarter 2 of 2010 (0.7% of all PCIs performed) to a peak of 6829 procedures between quarter 3 of 2015 and quarter 2 of 2016 (1.3% of all PCIs performed) ( Figure 1 ). Age and sex were similar across the study period between patients undergoing ULM PCI and patients undergoing all other PCI. However, rates of medical comorbidities increased significantly in those undergoing ULM PCI. Estimated risk of inpatient mortality increased over time, from 2.2% to 2.5% (P = .02) (eTable 1 in the Supplement).
Use [1281] ; P < .001). Rates of atherectomy increased over the study period from 6.9% (465) to 9.4% (641) (P < .001); atherectomy was mainly rotational but with an increasing proportion of orbital atherectomy (0% to 22.5% [144 of 641] of all atherectomy; P < .001) (eTable 2 in the Supplement).
Composite rates of in-hospital death, MI, stroke, or emergent CABG decreased over time (2009-2011, 9.3% [620 of 6696]; 2015-2016, 7 .8% [532 of 6829]; P = .01). Individual rates of MI also decreased over time (2009-2011, 4.5% [303]; 2015-2016, 2.5% [169] ; P < .001), while rates of death, stroke, and emergent CABG did not differ significantly (eTable 3 in the Supplement).
Variation in Performance of ULM PCI
The mean (SD) annualized volume of ULM PCI across operators in the CathPCI Registry was 0.5 (1.5) procedures, with only 1808 operators (16.7%) averaging 1 or more ULM PCI annually ( Figure 2A) . Discounting all operators averaging less than 1 ULM PCI annually over the study period, the trimmed operator mean (SD) annual volume was 2.5 (2.8) ULM PCI per year ( Figure 2B ). Figure 2C ). Discounting all institutions averaging less than 1 ULM PCI annually over the study period, the trimmed institutional mean (SD) annual volume was 5.7 (7.4) ULM PCI per year ( Figure 2D ). Among institutions performing at least 1 ULM PCI annually, the median annualized volume was 3.31 ULM PCI per year. Professional guidelines continue to recommend consideration of both ULM PCI and surgical revascularization for treatment of left main stenoses, incorporating patient and anatomic complexity into decision making. However, in contrast to clinical trials, the present analysis demonstrates significantly worse outcomes for a contemporary cohort undergoing ULM PCI in the United States as well as major differences in demographic, clinical, and procedural characteristics. Much of this demonstrated difference in outcomes is likely attributable to patient and procedural factors, with age and burden of comorbidities greater among patients in the CathPCI Registry than those reported in clinical trials, and procedural distinctions, such as the use of intravascular imaging. The difference in patient populations is further highlighted by the nearly 5-fold increase in use of MCS among patients in the CathPCI Registry compared with in clinical trials. With a higher burden of comorbidities among patients undergoing ULM PCI, it is possible that there is significant selection bias in management strategies wherein more clinically complex patients may undergo percutaneous rather than surgical revascularization in clinical practice. 20 Additionally, these findings suggest that PCI is an infrequently used management strategy for ULM stenoses. The estimated prevalence of left main disease found during diagnostic angiography is 6% in published series. 21, 22 With more than 1 million coronary angiograms performed annually in the United States, 23 the annual number of patients undergoing ULM PCI is quite low in ). Furthermore, there is significant variability in the frequency of ULM PCI performance across registry operators and institutions. Taken together, these findings suggest that ULM PCI is performed in older patients with high degrees of morbidity, performed with significant variability in operator and institutional procedural experience, and represents a minority of the management of left main stenosis. This raises the possibility that operator and institutional inexperience may play a role in addition to patient and procedural features in the observed difference in outcomes.
There are several possibilities to explain the limited rates of ULM PCI in contemporary practice. One is likely the comfort and experience that referring physicians have with CABG. Its historical efficacy and operator and institutional experience may influence referring physicians to send patients with ULM stenosis for coronary artery bypass surgery despite data suggesting equivalent short-term and mid-term outcomes in patients with lower anatomic complexity. It is also possible that clinicians see that real-world outcomes for patients undergoing ULM PCI-many of whom are older, frail, and may be determined to be at prohibitive risk for surgery-compare unfavorably with patients undergoing both all other PCI as well as CABG, leaving practitioners hesitant to refer younger, healthier patients for ULM PCI and further propagating the demonstrated differences in case mix. Third, it is likely that high-risk patients and procedures, like the older and comorbid patients presenting with acute coronary syndromes in this registry population, would be less likely to be enrolled in clinical trials, underscoring another important difference when considering trial results in the context of clinical practice. Fourth, it is possible that through a combination of low overall use and diffusion of higher-risk cases across operators and centers, operators and institutions are less comfortable performing ULM PCI compared with operators involved in randomized trials. The observed rates of 3.2 ULM PCI per year for institutions and 0.5 ULM PCI per year for operators in clinical practice are fractions of the rates published in clinical trials, with an institutional average of 7. 
Study Limitations
The findings of the present analysis should be interpreted while considering several limitations. First, as an observational analysis, residual confounding may be present and could bias findings. Demonstrated differences in demographic and clinical characteristics between patients undergoing ULM PCI vs not undergoing ULM PCI suggest selective use of ULM PCI in high-risk patients at participating CathPCI Registry institutions. These differences limit comparison with other published studies but underscore the restricted use of a viable treatment modality of ULM revascularization. Second, use of registry data requires assumptions that data are reported completely and accurately. While error in data collection or entry is possible, the NCDR CathPCI Registry undergoes periodic auditing to ensure optimal data integrity. Third, we were unable to ascertain longitudinal outcomes for patients undergoing ULM PCI, as postdischarge data are not available in the CathPCI Registry. Fourth, we were unable to compare treatment with ULM PCI with CABG or medical therapy. These groups are important for understanding the entirety of management of patients with ULM stenoses as well as clinical outcomes and factors associated with patient, operator, or institutional determination of treatment strategy and represent an opportunity for further study. Finally, the inability to calculate SYNTAX scores limited our ability to define the influence of anatomic complexity on outcomes and limited our ability to characterize compliance with past and current guideline recommendations.
Conclusions
Among patients treated at institutions participating in the CathPCI Registry, ULM PCI occurs infrequently and in an older and more comorbid population than those represented in clinical trials. While ULM PCI increased over the study period, operator and institutional volumes remained variable and limited, and outcomes were significantly worse than those seen in clinical trials. These findings suggest that randomized clinical trials demonstrating safety and efficacy of ULM PCI do not reflect contemporary clinical practice and suggest an opportunity to refine patient selection and increase operator and institutional experience as potential means to improving outcomes. ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Coll Cardiol. 2010; 55(18):1923 -1932 . doi:10.1016 /j.jacc.2010 
Risk Model
Cath PCI Mortality (%; mean ± SD)
2.2 ± 7.5 2.2 ± 7.2 2.4 ± 7.9 2.5 ± 8. All values reported as n (%) unless otherwise specified. a MCS = mechanical circulatory support b DES = drug eluting stent c Co Cr EES = cobalt chromium everolimus eluting stent d Pl Cr EES = platinum chromium everolimus eluting stent e ZES = zotarolimus eluting stent f PES = paclitaxel eluting stent g SES = sirolimus eluting stent 
